Chemopreventive and Anti-Cancer Efficacy of Silibinin Against Growth and Progression of Lung Cancer

REFERENCES

• Amercian Cancer Society . 2012 . Cancer Facts and Figures .
   Google Scholar
• Denlinger , C E , Ikonomidis , J S , Reed , C E and Spinale , F G . 2010 . Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers . J Thorac Cardiovasc Surg , 140 : 505 – 513 .
   PubMed Web of Science ®Google Scholar
• Travis , W D . 2011 . Classification of lung cancer . Semin Roentgenol , 46 : 178 – 186 .
   PubMed Web of Science ®Google Scholar
• Schiller , J H . 2001 . Current standards of care in small-cell and non-small-cell lung cancer . Oncology , 61 ( 1 ) : 3 – 13 .
   PubMed Web of Science ®Google Scholar
• Collins , L G , Haines , C , Perkel , R and Enck , R E . 2007 . Lung cancer: diagnosis and management . Am Fam Physician , 75 : 56 – 63 .
   PubMed Web of Science ®Google Scholar
• Spira , A and Ettinger , D S . 2004 . Multidisciplinary management of lung cancer . N Engl J Med , 350 : 379 – 392 .
   PubMed Web of Science ®Google Scholar
• Mountain , C F . 1997 . Revisions in the International System for Staging Lung Cancer . Chest , 111 : 1710 – 1717 .
   PubMed Web of Science ®Google Scholar
• Molina , J R , Yang , P , Cassivi , S D , Schild , S E and Adjei , A A . 2008 . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship . Mayo Clin Proc , 83 : 584 – 594 .
   PubMed Web of Science ®Google Scholar
• Molina , J R , Adjei , A A and Jett , J R . 2006 . Advances in chemotherapy of non-small cell lung cancer . Chest , 130 : 1211 – 1219 .
   PubMed Web of Science ®Google Scholar
• Sorenson , S , Glimelius , B and Nygren , P . 2001 . A systematic overview of chemotherapy effects in non-small cell lung cancer . Acta Oncol , 40 : 327 – 339 .
   PubMed Web of Science ®Google Scholar
• D’Addario , G , Pintilie , M , Leighl , N B , Feld , R Cerny , T . 2005 . Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature . J Clin Oncol , 23 : 2926 – 2936 .
   PubMed Web of Science ®Google Scholar
• Sun , S , Schiller , J H , Spinola , M and Minna , J D . 2007 . New molecularly targeted therapies for lung cancer . J Clin Invest , 117 : 2740 – 2750 .
   PubMed Web of Science ®Google Scholar
• Burris , H A 3rd . 2009 . Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs . Oncogene , 28 ( 1 ) : S4 – 13 .
   PubMed Web of Science ®Google Scholar
• Giaccone , G . 2004 . Twenty-five years of treating advanced NSCLC: what have we achieved? . Ann Oncol , 15 ( 4 ) : 81 – 83 .
   Web of Science ®Google Scholar
• Neal , J W and Sequist , L V . 2010 . Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh . Curr Treat Options Oncol , 11 : 36 – 44 .
   PubMed Web of Science ®Google Scholar
• Sangha , R , Lara , P N Jr. , Mack , P C and Gandara , D R . 2009 . Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier . Curr Opin Oncol , 21 : 116 – 123 .
   PubMed Web of Science ®Google Scholar
• Surh , Y J . 2003 . Cancer chemoprevention with dietary phytochemicals . Nat Rev Cancer , 3 : 768 – 780 .
   PubMed Web of Science ®Google Scholar
• Cohen , V and Khuri , F R . 2003 . Progress in lung cancer chemoprevention . Cancer Control , 10 : 315 – 324 .
   PubMedGoogle Scholar
• Cohen , V and Khuri , F R . 2004 . Chemoprevention of lung cancer . Curr Opin Pulm Med , 10 : 279 – 283 .
   PubMed Web of Science ®Google Scholar
• Soria , J C , Kim , E S , Fayette , J , Lantuejoul , S Deutsch , E . 2003 . Chemoprevention of lung cancer . Lancet Oncol , 4 : 659 – 669 .
   PubMed Web of Science ®Google Scholar
• Sporn , M B . 1993 . Chemoprevention of cancer . Lancet , 342 : 1211 – 1213 .
   PubMed Web of Science ®Google Scholar
• Russo , G L . 2007 . Ins and outs of dietary phytochemicals in cancer chemoprevention . Biochem Pharmacol , 74 : 533 – 544 .
   PubMed Web of Science ®Google Scholar
• Tsao , A S , Kim , E S and Hong , W K . 2004 . Chemoprevention of cancer . CA Cancer J Clin , 54 : 150 – 180 .
   PubMed Web of Science ®Google Scholar
• van Zandwijk , N and Hirsch , F R . 2003 . Chemoprevention of lung cancer: current status and future prospects . Lung Cancer , 42 ( 1 ) : S71 – 79 .
   PubMed Web of Science ®Google Scholar
• Mehta , R G , Murillo , G , Naithani , R and Peng , X . 2010 . Cancer chemoprevention by natural products: how far have we come? . Pharm Res , 27 : 950 – 961 .
   PubMed Web of Science ®Google Scholar
• Omenn , G S . 2007 . Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future . Eur J Cancer Prev , 16 : 184 – 191 .
   PubMed Web of Science ®Google Scholar
• Omenn , G S . 2004 . Human lung cancer chemoprevention strategies: Parker B. Francis lecture . Chest , 125 : 123S – 127S .
   PubMed Web of Science ®Google Scholar
• Winterhalder , R C , Hirsch , F R , Kotantoulas , G K , Franklin , W A and Bunn , P A Jr. 2004 . Chemoprevention of lung cancer–from biology to clinical reality . Ann Oncol , 15 : 185 – 196 .
   PubMed Web of Science ®Google Scholar
• Cohen , V and Khuri , F R . 2002 . Chemoprevention of lung cancer: current status and future prospects . Cancer Metastasis Rev , 21 : 349 – 362 .
   PubMed Web of Science ®Google Scholar
• Lam , S , McWilliams , A , LeRiche , J , MacAulay , C Wattenberg , L . 2006 . A phase I study of myo-inositol for lung cancer chemoprevention . Cancer Epidemiol Biomarkers Prev , 15 : 1526 – 1531 .
   PubMed Web of Science ®Google Scholar
• Lippman , S M , Lee , J J , Karp , D D , Vokes , E E Benner , S E . 2001 . Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer . J Natl Cancer Inst , 93 : 605 – 618 .
   PubMed Web of Science ®Google Scholar
• Kim , K W , Choi , C H , Kim , T H , Kwon , C H Woo , J S . 2009 . Silibinin inhibits glioma cell proliferation via Ca2+/ROS/MAPK-dependent mechanism in vitro and glioma tumor growth in vivo . Neurochem Res , 34 : 1479 – 1490 .
   PubMed Web of Science ®Google Scholar
• Keith , R L . 2009 . Chemoprevention of lung cancer . Proc Am Thorac Soc , 6 : 187 – 193 .
   PubMedGoogle Scholar
• Ramasamy , K and Agarwal , R . 2008 . Multitargeted therapy of cancer by silymarin . Cancer Lett , 269 : 352 – 362 .
   PubMed Web of Science ®Google Scholar
• Singh , R P and Agarwal , R . 2004 . Prostate cancer prevention by silibinin . Curr Cancer Drug Targets , 4 : 1 – 11 .
   PubMed Web of Science ®Google Scholar
• Singh , R P and Agarwal , R . 2005 . Mechanisms and preclinical efficacy of silibinin in preventing skin cancer . Eur J Cancer , 41 : 1969 – 1979 .
   PubMed Web of Science ®Google Scholar
• Singh , R P and Agarwal , R . 2006 . Prostate cancer chemoprevention by silibinin: bench to bedside . Mol Carcinog , 45 : 436 – 442 .
   PubMed Web of Science ®Google Scholar
• Agarwal , R , Agarwal , C , Ichikawa , H , Singh , R P and Aggarwal , B B . 2006 . Anticancer potential of silymarin: from bench to bed side . Anticancer Res , 26 : 4457 – 4498 .
   PubMed Web of Science ®Google Scholar
• Post-White , J , Ladas , E J and Kelly , K M . 2007 . Advances in the use of milk thistle (Silybum marianum) . Integr Cancer Ther , 6 : 104 – 109 .
   PubMed Web of Science ®Google Scholar
• Pradhan , S C and Girish , C . 2006 . Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine . Indian J Med Res , 124 : 491 – 504 .
   PubMed Web of Science ®Google Scholar
• Rainone , F . 2005 . Milk thistle . Am Fam Physician , 72 : 1285 – 1288 .
   PubMed Web of Science ®Google Scholar
• Kroll , D J , Shaw , H S and Oberlies , N H . 2007 . Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies . Integr Cancer Ther , 6 : 110 – 119 .
   PubMed Web of Science ®Google Scholar
• Chittezhath , M , Deep , G , Singh , R P , Agarwal , C and Agarwal , R . 2008 . Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells . Mol Cancer Ther , 7 : 1817 – 1826 .
   PubMed Web of Science ®Google Scholar
• Mateen , S , Tyagi , A , Agarwal , C , Singh , R P and Agarwal , R . 2010 . Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators . Mol Carcinog , 49 : 247 – 258 .
   PubMed Web of Science ®Google Scholar
• Ramasamy , K , Dwyer-Nield , L D , Serkova , N J , Hasebroock , K M Tyagi , A . 2011 . Silibinin prevents lung tumorigenesis in wild-type but not in iNOS−/− mice: potential of real-time micro-CT in lung cancer chemoprevention studies . Clin Cancer Res , 17 : 753 – 761 .
   PubMed Web of Science ®Google Scholar
• Singh , R P , Deep , G , Chittezhath , M , Kaur , M Dwyer-Nield , L D . 2006 . Effect of silibinin on the growth and progression of primary lung tumors in mice . J Natl Cancer Inst , 98 : 846 – 855 .
   PubMed Web of Science ®Google Scholar
• Tyagi , A , Agarwal , C , Dwyer-Nield , L D , Singh , R P Malkinson , A M . 2011 . Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells . Mol Carcinog ,
   Web of Science ®Google Scholar
• Sharma , G , Singh , R P , Chan , D C and Agarwal , R . 2003 . Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells . Anticancer Res , 23 : 2649 – 2655 .
   PubMed Web of Science ®Google Scholar
• Deep , G and Agarwal , R . 2010 . Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer . Cancer Metastasis Rev , 29 : 447 – 463 .
   PubMed Web of Science ®Google Scholar
• Raina , K , Rajamanickam , S , Singh , R P , Deep , G Chittezhath , M . 2008 . Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model . Cancer Res , 68 : 6822 – 6830 .
   PubMed Web of Science ®Google Scholar
• Chen , P N , Hsieh , Y S , Chiang , C L , Chiou , H L Yang , S F . 2006 . Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway . J Dent Res , 85 : 220 – 225 .
   PubMed Web of Science ®Google Scholar
• Chu , S C , Chiou , H L , Chen , P N , Yang , S F and Hsieh , Y S . 2004 . Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2 . Mol Carcinog , 40 : 143 – 149 .
   PubMed Web of Science ®Google Scholar
• Singh , R P , Mallikarjuna , G U , Sharma , G , Dhanalakshmi , S Tyagi , A K . 2004 . Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance . Clin Cancer Res , 10 : 8641 – 8647 .
   PubMed Web of Science ®Google Scholar
• Rho , J K , Choi , Y J , Jeon , B S , Choi , S J Cheon , G J . 2010 . Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation . Mol Cancer Ther , 9 : 3233 – 3243 .
   PubMed Web of Science ®Google Scholar
• Tyagi , A , Singh , R P , Ramasamy , K , Raina , K Redente , E F . 2009 . Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3 . Cancer Prev Res (Phila) , 2 : 74 – 83 .
   PubMed Web of Science ®Google Scholar
• Dagne , A , Melkamu , T , Schutten , M M , Qian , X Upadhyaya , P . 2011 . Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J mice . Carcinogenesis , 32 : 561 – 567 .
   PubMed Web of Science ®Google Scholar
• Yan , Y , Wang , Y , Tan , Q , Lubet , R A and You , M . 2005 . Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice . Neoplasia , 7 : 1053 – 1057 .
   PubMed Web of Science ®Google Scholar
• Belinsky , S A , Klinge , D M , Stidley , C A , Issa , J P Herman , J G . 2003 . Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer . Cancer Res , 63 : 7089 – 7093 .
   PubMed Web of Science ®Google Scholar
• Jones , P A and Baylin , S B . 2007 . The epigenomics of cancer . Cell , 128 : 683 – 692 .
   PubMed Web of Science ®Google Scholar
• Risch , A and Plass , C . 2008 . Lung cancer epigenetics and genetics . Int J Cancer , 123 : 1 – 7 .
   PubMed Web of Science ®Google Scholar
• Mateen , S , Raina , K , Agarwal , C and Agarwal , R . Inhibition of Epigenetic Chromatin-Modification Enzymes: Histone Deacetylases and DNA Methyltransferases by Silibinin in human NSCLC H1299 cells . 101 st Annual Meeting of AACR , Washington, D.C. , , USA April (abstr)
   Google Scholar
• Witt , O , Deubzer , H E , Milde , T and Oehme , I . 2009 . HDAC family: What are the cancer relevant targets? . Cancer Lett , 277 : 8 – 21 .
   PubMed Web of Science ®Google Scholar
• Bots , M and Johnstone , R W . 2009 . Rational combinations using HDAC inhibitors . Clin Cancer Res , 15 : 3970 – 3977 .
   PubMed Web of Science ®Google Scholar
• Song , S H , Han , S W and Bang , Y J . 2011 . Epigenetic-based therapies in cancer: progress to date . Drugs , 71 : 2391 – 2403 .
   PubMed Web of Science ®Google Scholar
• Mateen , S , Raina , K , Jain , A K , Agarwal , C , Chan , D and Agarwal , R . 2012 . Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells . Epigenetics , 7 : 1161 – 1172 .
   PubMed Web of Science ®Google Scholar
• Mateen , S , Raina , K , Agarwal , C , Chan , D and Agarwal , R . 2013 . Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Upregulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells . The Journal of pharmacology and experimental therapeutics , 345 : 206 – 214 .
   PubMed Web of Science ®Google Scholar
• Witta , S E , Gemmill , R M , Hirsch , F R , Coldren , C D Hedman , K . 2006 . Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines . Cancer Res , 66 : 944 – 950 .
   PubMed Web of Science ®Google Scholar
• Richardson , F , Young , G D , Sennello , R , Wolf , J Argast , G M . 2012 . The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy . Anticancer Res , 32 : 537 – 552 .
   PubMed Web of Science ®Google Scholar